title: Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.
abstract: We assessed the therapeutic benefits of 131I treatment in patients with distant metastases of differentiated thyroid carcinoma.
  
  
  METHODS
  Of 2200 patients treated for differentiated thyroid carcinoma at our institution, 394 had lung and/or bone metastases.
  
  
  RESULTS
  Two-thirds of the patients had 131I uptake in their metastases, but only 46% achieved a complete response. Prognostic factors for complete response were: younger age, presence of 131I uptake in the metastases and small extent of disease. The survival rate was 33% at 15 yr. As shown by multivariate analysis, favorable prognostic factors for survival were: younger age and time of metastases detection, well-differentiated histologic type of the thyroid tumor, presence of 131I type uptake in the metastases, small extent of the disease and year of discovery of metastases.
  
  
  CONCLUSIONS
  In terms of survival, the benefits of 131I therapy cannot be demonstrated by prospective controlled studies. The present study clearly demonstrates, however, that treatment with 131I is one of the factors which accounts for survival; patients whose metastases concentrated 131I and who could be treated with radioiodine had higher survival rates. Patients who achieved complete response following treatment of distant metastases had a 15-yr survival rate of 89%, while those who did not achieve complete response had a survival rate of only 8%. The survival rate improved with the year of discovery of distant metastases, after 131I total-body imaging and serum thyroglobulin measurements were routinely used.
authors.affiliation: Institut Gustave-Roussy, Villejuif, France.
authors.forename: M
authors.initials: M
authors.lastname: Schlumberger
authors.forename: C
authors.initials: C
authors.lastname: Challeton
authors.forename: F
authors.initials: F
authors.lastname: De Vathaire
authors.forename: J P
authors.initials: JP
authors.lastname: Travagli
authors.forename: P
authors.initials: P
authors.lastname: Gardet
authors.forename: J D
authors.initials: JD
authors.lastname: Lumbroso
authors.forename: C
authors.initials: C
authors.lastname: Francese
authors.forename: F
authors.initials: F
authors.lastname: Fontaine
authors.forename: M
authors.initials: M
authors.lastname: Ricard
authors.forename: C
authors.initials: C
authors.lastname: Parmentier
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000401:mortality / Q000532:radiotherapy / Q000556:secondary; D000293:Adolescent; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D002291:Carcinoma, Papillary / Q000401:mortality / Q000532:radiotherapy / Q000556:secondary; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D016015:Logistic Models; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000473:pathology*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D013954:Thyroglobulin